CCXI - CCXI STOCK NEWS

ChemoCentryx announced an amendment to its NDA for avacopan to treat ANCA-associated vasculitis, with a new PDUFA date of October 7, 2021. The company has $402.6 million in cash and investments as of June 30, 2021. Financial results showed a revenue drop to $1.8 million from $49.4 million year-over-year due to prior revenue acceleration. R&D expenses rose to $20.9 million, while G&A expenses increased to $19.7 million. The net loss for Q2 2021 was $39.2 million, down from a profit in 2020. Clinical development for CCX559 as a next-gen checkpoint inhibitor has commenced.

ChemoCentryx, a biopharmaceutical company, announced that CEO Thomas J. Schall will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 5:00 p.m. ET. A live audio webcast of the event will be accessible on the company’s website, with a replay available for two weeks post-event. ChemoCentryx focuses on developing therapies for inflammatory and autoimmune diseases, notably through its lead candidate, avacopan (CCX168), which is in late-stage clinical development for several conditions.

ChemoCentryx, Inc. (Nasdaq: CCXI) will release its second quarter 2021 financial results after market close on August 9, 2021. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results. Interested participants can join by calling (877) 303-8028 domestically or (760) 536-5167 internationally. The company's lead drug candidate, avacopan (CCX168), is in late-stage clinical development for severe Hidradenitis Suppurativa and C3 glomerulopathy, following a successful Phase III trial in ANCA-associated vasculitis.

ChemoCentryx, Inc. (Nasdaq: CCXI) has filed a major amendment to its New Drug Application (NDA) for avacopan, aimed at treating ANCA-associated vasculitis, responding to concerns raised during an FDA Advisory Committee meeting. The FDA established a new PDUFA goal date of October 7, 2021. The FDA advisory committee voted inconclusively on avacopan's efficacy but acknowledged its safety. ChemoCentryx is also pursuing approval in Europe and Japan, where applications have been validated. Avacopan is a targeted therapy aimed at reducing the risks associated with current treatments.

ChemoCentryx (Nasdaq: CCXI) announced that its CEO, Thomas J. Schall, Ph.D., will participate in a fireside chat at the Raymond James 2021 Human Health Innovations Conference on June 23 at 10:40 a.m. ET. A live audio webcast will be available on the company’s website, with a replay accessible for two weeks post-event.

ChemoCentryx focuses on developing new medications for inflammatory and autoimmune diseases, with its lead drug candidate, avacopan (CCX168), under FDA review following a successful Phase III trial.

ChemoCentryx (Nasdaq: CCXI) presented key outcomes from its Phase III ADVOCATE trial and Phase II ACCOLADE and LUMINA-1 trials at the ERA-EDTA annual meeting. Notably, the ADVOCATE trial's abstract received recognition as one of the top ten presentations, showcasing avacopan's ability to improve kidney function in patients with ANCA-associated vasculitis. Additionally, the ACCOLADE study, which evaluated avacopan for C3G glomerulopathy, displayed promising preliminary results, though further validation is needed. The company has also decided not to pursue CCX140's development for FSGS.

ChemoCentryx, Inc. (Nasdaq: CCXI) reported on the FDA Arthritis Advisory Committee's evaluation of avacopan for treating ANCA-associated vasculitis. The Committee's votes were split: 9-9 on efficacy, 10-8 on safety, and 10-8 on the drug's benefit-risk profile. ChemoCentryx acknowledged the Committee's deliberations and the urgent need for new treatments. Avacopan is a first-in-class, oral therapy targeting the complement system, and has been granted orphan drug designation by the FDA for ANCA-associated vasculitis.

ChemoCentryx, Inc. (CCXI) announced its first-quarter financial results, reporting $10.4 million in revenue, up from $6.0 million year-over-year, primarily due to a $10 million milestone payment from Vifor Pharma. The company holds $424 million in cash and investments. Avacopan, under regulatory review for ANCA-associated vasculitis, is set for a PDUFA goal date on July 7, 2021. Clinical trials for avacopan in severe Hidradenitis Suppurativa and lupus nephritis are planned for 2H 2021. The novel checkpoint inhibitor CCX559 is expected to enter clinical development in Q2 2021.

ChemoCentryx, Inc. (Nasdaq: CCXI) will release its first quarter 2021 financial results on April 29, 2021, post market close. A conference call to discuss these results will follow at 5:00 p.m. ET. ChemoCentryx is known for developing treatments for inflammatory diseases and cancer, with its lead candidate, avacopan (CCX168), under FDA review after a successful Phase III trial for ANCA-associated vasculitis. The drug is also in late-stage development for other serious conditions.